Who uses Illumina NextSeq?
NextSeq is a benchtop short-read sequencer sized for a lab or core: RNA-seq, single-cell libraries, gene panels and exomes. It's made by Illumina. 4,385 bioRxiv and medRxiv preprints since April 2025 say they used NextSeq, 1,169 in the last 6 months. Updated daily (as of Nov 16)
Is NextSeq use still growing?
No: 1,169 preprints used NextSeq in Jun–Nov 2026, -19% vs the previous year as a share of all preprints. This is slower than short-read sequencers overall (+8%).
The last bar is the quarter so far. The % over each year compares it with the year before, as a share of all preprints.
How does NextSeq compare with other short-read sequencers?
NextSeq is second, with 40% of their uses in Jun–Nov 2026, down from 53% the year before. NovaSeq X leads with 44%.
Which institutions use NextSeq most?
The institutions using NextSeq most are University of Washington, Stanford University and University of Pennsylvania.
Institutions
University of Washington61
Stanford University54
University of Pennsylvania48
Institut Pasteur48
University of Pittsburgh40
Where the labs are
The lab's institution and country are the corresponding author's.
Latest preprints using NextSeq
Who started using NextSeq recently?
189 institutions posted their first preprint using NextSeq since April 2025 in the last 6 months, including Real Jardín Botánico (CSIC), University of Colorado Anschutz Medical Campus and University of Salamanca.
Real Jardín Botánico (CSIC)Jul 17, 2026
University of Colorado Anschutz Medical CampusJul 23, 2026
University of SalamancaJul 9, 2026
Florey Institute of Neuroscience and Mental HealthJun 2, 2026
Victor Chang Cardiac Research InstituteJun 10, 2026
Earlham InstituteJun 15, 2026
Justus Liebig University GiessenJun 26, 2026
Shanghai Institute of Materia MedicaJul 10, 2026
University of SurreyJul 17, 2026
Aarhus UniversityAug 28, 2026
An institution counts as new when its first preprint using NextSeq since April 2025 was posted in the last 6 months; the date is that first preprint.
What do labs use alongside NextSeq?
Preprints using NextSeq most often also use Chromium, NovaSeq X and FACSymphony. The count is preprints using both.
What is NextSeq used for?
Preprints using NextSeq are most often in microbiology, cancer biology and immunology.
Fields
Microbiology 672Cancer biology 431Immunology 384Molecular biology 378Genomics 355Neuroscience 308
Where the work was published
- Nature Communications66
- Proceedings of the National Academy of Sciences41
- Nucleic Acids Research30
- Cell Reports26
- Scientific Reports24
- mBio23
How we count which preprints use each platform
An AI model reads each preprint in full — its text, its tables and its supplementary files — and lists the products the authors used. A preprint counts for a platform when that record says the lab used it in this work, not when it only analyzed data others made with it or only mentioned it. Each preprint counts once, by its first version, if it was first posted on bioRxiv or medRxiv in April 2025 or later. We read new preprints within days of posting, so the newest ones (through Nov 16, 2026) are already counted, but those days are not complete yet. Six-month counts and growth figures stop at Nov 12, 2026, the last day nearly every preprint has been read, and charts draw a quarter that is still being counted in a paler color. A preprint that used two platforms counts for both. Each title links to the preprint on bioRxiv or medRxiv; we show no preprint text and no author names. Updated daily, most recently on Nov 16, 2026.